1/8/2010

Molecular Insight Pharmaceuticals, a developer of targeted drugs and imaging radiopharmaceuticals, has announced its plan to eliminate nine positions in order to cut costs and further support its oncology pipeline. The company expects to save about $1 million annually as a result of the move.

Full Story:
MarketWire

Related Summaries